Pancreatic Cancer Research

ResearcherTohoku UniversityActive in the last 2 years

Yuichiro Doki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7346-0209; OpenAlex author ID A5009807059, A5028284770, A5113595758, A5123229899. Sources: OpenAlex.

Their work

Papers
107 (first author 0, last author 28)
Trials
0
Grants
0
Labs led
1
Collaborators
117
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 7 papers · 2014: 5 papers · 2015: 9 papers · 2016: 4 papers · 2017: 11 papers · 2018: 7 papers · 2019: 3 papers · 2020: 6 papers · 2021: 3 papers · 2022: 8 papers · 2023: 7 papers · 2024: 16 papers · 2025: 10 papers · 2026: 7 papers

Papers 50 of 107

  1. Relationship Between Radiographic and Pathological Portal Vein-Superior Mesenteric Vein Involvement in Neoadjuvant Treatment for Pancreatic Cancer: A Comparati… Co-author DOI 10.1002/wjs.70395↗
  2. A soft tissue mass around the arteries after pancreatectomy: the association with local recurrence and the impact of neoadjuvant radiotherapy in pancreatic duc… Co-author DOI 10.1007/s00595-026-03341-w↗
  3. A prospective open label, multicenter phase 2 trial of full-dose gemcitabine and S-1 concurrent with radiation for locally advanced pancreatic ductal adenocarc… Co-author DOI 10.1007/s00595-026-03481-z↗
  4. Prognostic significance of neoadjuvant gemcitabine and S-1 chemotherapy with or without concurrent radiation in patients with resectable and borderline resecta… Co-author DOI 10.1016/j.surg.2025.109864↗
  5. Exosomal microRNA-4800-3p in portal vein blood promotes liver metastasis in pancreatic cancer by targeting PLAA. Co-author DOI 10.1038/s41598-026-48779-7↗
  6. Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027). Co-author DOI 10.1371/journal.pone.0345459↗
  7. Circ72309 modulates gemcitabine metabolism and gemcitabine sensitivity in pancreatic cancer: Serum Circ72309 levels as a potential predictor of treatment respo… Co-author DOI 10.3892/ijo.2026.5849↗
  8. Discrepancy Between Radiographic and Pathological Response Assessment in Neoadjuvant Treatment for Pancreatic Cancer: A Comparison Between Neoadjuvant Chemothe… Co-author DOI 10.1002/ags3.70047↗
  9. Prognostic impact of post-neoadjuvant CA19-9 values in pancreatic cancer: more pronounced following neoadjuvant chemotherapy compared to neoadjuvant chemoradio… Co-author DOI 10.1016/j.pan.2025.06.016↗
  10. Response to the letter to the editor: "Refining the prognostic utility of CA19-9 in neoadjuvant therapy for pancreatic cancer: Emphasizing serial monitoring an… Co-author DOI 10.1016/j.pan.2025.09.033↗
  11. Surgical outcomes of histopathological stage I pancreatic cancer with special reference to oncological differences between pStage I and ypStage I cases. Co-author DOI 10.1016/j.suronc.2025.102225↗
  12. Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenoca… Co-author DOI 10.1038/s41598-025-23185-7↗
  13. The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was independent of intratumoral vascularization. Co-author DOI 10.1186/s12876-025-04108-2↗
  14. miR-6855-5p Enhances Radioresistance and Promotes Migration of Pancreatic Cancer by Inducing Epithelial-Mesenchymal Transition via Suppressing FOXA1: Potential… Co-author DOI 10.1245/s10434-024-16115-w↗
  15. ASO Author Reflections: Potential of Peripheral Plasma Exosomal miRNA: miR-6855-5p Could Predict Radiosensitivity in Patients with Pancreatic Cancer, and Enhan… Co-author DOI 10.1245/s10434-024-16235-3↗
  16. Efficacy of SOAT1 Inhibitors Against Pancreatic Cancer with TP53 Mutations. Co-author DOI 10.1245/s10434-025-17482-8↗
  17. ASO Author Reflections: Efficacy of SOAT1 Inhibitors against Pancreatic Cancer with TP53 Mutations. Co-author DOI 10.1245/s10434-025-17667-1↗
  18. Removal of gemcitabine-induced senescent cancer cells by targeting glutaminase1 improves the therapeutic effect in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.34725↗
  19. Prognostic impact of aberrant right hepatic artery involvement in patients with pancreatic cancer: A multicenter retrospective cohort study. Co-author DOI 10.1002/jso.27792↗
  20. Diagnostic impact of postoperative CA19-9 dynamics on pancreatic cancer recurrence: a single-institution retrospective study. Co-author DOI 10.1007/s13304-024-01758-x↗
  21. Preoperative nutritional status is a useful predictor of the feasibility of postoperative treatment in octogenarian-plus pancreatic ductal adenocarcinoma patie… Co-author DOI 10.1016/j.ejso.2024.108650↗
  22. Preoperative treatment response prediction for pancreatic cancer by multiple microRNAs in plasma exosomes: Optimization using machine learning and network anal… Co-author DOI 10.1016/j.pan.2024.09.009↗
  23. Organ-specific variations in tumor marker dynamics in postoperative pancreatic cancer recurrence: Trends in lung and liver recurrence highlighting biological h… Co-author DOI 10.1016/j.suronc.2024.102103↗
  24. High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker. Co-author DOI 10.1111/cas.16152↗
  25. ASO Author Reflections: A Novel Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers Enhances Predictive Significance in Patients with a Modest Radi… Co-author DOI 10.1245/s10434-024-15021-5↗
  26. Skeletal Muscle-Derived Irisin Enhances Gemcitabine Sensitivity and Suppresses Migration Ability in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15118-x↗
  27. Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline… Co-author DOI 10.1245/s10434-024-15199-8↗
  28. ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pa… Co-author DOI 10.1245/s10434-024-15244-6↗
  29. ASO Author Reflections: A Novel Mechanism of Anticancer Effect of Skeletal Muscle-Derived Irisin in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15349-y↗
  30. MicroRNA-26a-5p is a reliable biomarker in the adjuvant setting for pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0310328↗
  31. Lymphocyte Antigen 6 Family Member D (LY6D) Affects Stem Cell Phenotype and Progression of Pancreatic Adenocarcinoma. Co-author DOI 10.21873/anticanres.17300↗
  32. Circulating tumor-associated antigen-specific IFNγ+4-1BB+ CD8+ T cells as peripheral biomarkers of treatment outcomes in patients with pancreatic cancer. Co-author DOI 10.3389/fimmu.2024.1363568↗
  33. Significance of signal recognition particle 9 nuclear translocation: Implications for pancreatic cancer prognosis and functionality. Co-author DOI 10.3892/ijo.2024.5662↗
  34. Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-023-04531-w↗
  35. Pancreatic cancer near the splenic hilum has a higher likelihood of splenic vessel invasion and unfavorable survival. Co-author DOI 10.1007/s00423-023-03089-8↗
  36. Rubicon can predict prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant chemoradiotherapy. Co-author DOI 10.1007/s10147-023-02306-0↗
  37. Multifaced roles of desmoplastic reaction and fibrosis in pancreatic cancer progression: Current understanding and future directions. Co-author DOI 10.1111/cas.15890↗
  38. Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma U… Co-author DOI 10.1245/s10434-022-12985-0↗
  39. ASO Author Reflections: Neoadjuvant Chemoradiotherapy for Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancre… Co-author DOI 10.1245/s10434-022-13024-8↗
  40. The impact of cellular senescence and senescence‑associated secretory phenotype in cancer‑associated fibroblasts on the malignancy of pancreatic cancer. Co-author DOI 10.3892/or.2023.8535↗
  41. Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cnr2.1582↗
  42. Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma. Co-author DOI 10.1016/j.isci.2022.104659↗
  43. N(6)-methyladenosine methylation-regulated polo-like kinase 1 cell cycle homeostasis as a potential target of radiotherapy in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-022-15196-5↗
  44. Circulating cancer-associated extracellular vesicles as early detection and recurrence biomarkers for pancreatic cancer. Co-author DOI 10.1111/cas.15500↗
  45. Inhibition of Clusterin Represses Proliferation by Inducing Cellular Senescence in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11668-0↗
  46. ASO Author Reflections: A Novel Mechanism of Suppressing Proliferation After Inhibition of Clusterin in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11745-4↗
  47. Emerging roles of long noncoding and circular RNAs in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fphys.2022.1025923↗
  48. Pancreatic Cancer Research beyond DNA Mutations. Co-author DOI 10.3390/biom12101503↗
  49. Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvan… Co-author DOI 10.1002/ags3.12418↗
  50. Inhibition of c-MET reverses radiation-induced malignant potential in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.04.029↗

Closest collaborators

The 25 strongest of 117 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hidetoshi Eguchi · 92 shared papers, 2011–2026 · strength 10.20
  2. Daisaku Yamada · 60 shared papers, 2015–2026 · strength 8.90
  3. Yoshito Tomimaru · 53 shared papers, 2013–2026 · strength 7.86
  4. Yoshifumi Iwagami · 51 shared papers, 2013–2026 · strength 7.46
  5. Tadafumi Asaoka · 55 shared papers, 2014–2026 · strength 7.10
  6. Hirofumi Akita · 41 shared papers, 2011–2026 · strength 5.96
  7. Hidenori Takahashi · 32 shared papers, 2011–2026 · strength 5.42
  8. Kazuki Sasaki · 29 shared papers, 2022–2026 · strength 5.23
  9. Masahiro Tanemura · 33 shared papers, 2011–2026 · strength 3.24
  10. Kunihito Gotoh · 29 shared papers, 2012–2024 · strength 2.69
  11. Yutaka Takeda · 23 shared papers, 2011–2026 · strength 2.23
  12. Shinichiro Hasegawa · 14 shared papers, 2014–2026 · strength 2.21
  13. Hideshi Ishii · 19 shared papers, 2014–2024 · strength 1.87
  14. Hidetoshi Eguchi · 8 shared papers, 2017–2026 · strength 1.68
  15. Satoru Miyahara · 6 shared papers, 2024–2026 · strength 1.37
  16. Hiroaki Nagano · 28 shared papers, 2011–2020 · strength 1.23
  17. Hiroki Ueda · 5 shared papers, 2023–2025 · strength 0.96
  18. Masahiko Kubo · 5 shared papers, 2020–2025 · strength 0.89
  19. Masanori Tsujie · 5 shared papers, 2021–2026 · strength 0.87
  20. Masaki Mori · 14 shared papers, 2011–2024 · strength 0.84
  21. Tomoaki Hara · 5 shared papers, 2022–2024 · strength 0.77
  22. Hiromichi Sato · 5 shared papers, 2022–2024 · strength 0.77
  23. Yu Takeda · 5 shared papers, 2020–2024 · strength 0.75
  24. Naoko Sekiguchi · 3 shared papers, 2025–2026 · strength 0.72
  25. Kazuhiko Ogawa · 6 shared papers, 2015–2024 · strength 0.68

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.